The excessive accumulation of platelets at sites of vascular injury is a key event in the development of arterial thrombosis, the principal pathogenic mechanism underlying the acute coronary syndromes and ischaemic stroke. In combination, these disorders are the leading causes of morbidity and mortality in the industrialised world and, as a consequence, the platelet is a major therapeutic target in the management of cardiovascular disease. This perspective focuses on the present state of antiplatelet therapy and potential future strategies to improve the safety and efficacy of antiplatelet agents.
|Pages (from-to)||1035 - 1040|
|Number of pages||6|
|Journal||Expert Opinion on Drug Discovery|
|Publication status||Published - 2007|